ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
08 janv. 2018 08h30 HE
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting
16 nov. 2017 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
09 août 2017 16h30 HE
|
ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...
ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017
20 juin 2017 08h30 HE
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA ...
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
15 mai 2017 08h30 HE
|
ARCA Biopharma, Inc.
WESTMINSTER, Colo., May 15, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio
19 mars 2014 07h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, CO--(Marketwired - Mar 19, 2014) - ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today...